Brexit and the pharmaceutical industry: What happens if there’s no deal?

Concerns about the possibility of a no-deal Brexit in March 2019, when the UK begins its transitional period to leave the EU, have been expressed repeatedly by the pharmaceutical industry. Most recently, AstraZeneca announced it would increase its stockpile of drugs by 20% after organisations, such as the Association of the British Pharmaceutical Industry (ABPI) … Continue reading Brexit and the pharmaceutical industry: What happens if there’s no deal?